Cytokines inNew‐OnsetRefractory Status Epilepticus Predict Outcomes
Top Cited Papers
- 17 March 2023
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 94 (1) , 75-90
Abstract
Objective: The objective of this study was to investigate inflammation using cerebrospinal fluid (CSF) and serum cytokines/chemokines in patients with new‐onset refractory status epilepticus (NORSE) to better understand the pathophysiology of NORSE and its consequences.Methods: Patients with NORSE (n = 61, including n = 51 cryptogenic), including its subtype with prior fever known as febrile infection‐related epilepsy syndrome (FIRES), were compared with patients with other refractory status epilepticus (RSE; n = 37), and control patients without SE (n = 52). We measured 12 cytokines/chemokines in serum or CSF samples using multiplexed fluorescent bead‐based immunoassay detection. Cytokine levels were compared between patients with and without SE, and between the 51 patients with cryptogenic NORSE (cNORSE) and the 47 patients with a known‐etiology RSE (NORSE n = 10, other RSE n = 37), and correlated with outcomes.Results: A significant increase of IL‐6, TNF‐α, CXCL8/IL‐8, CCL2, MIP‐1α, and IL‐12p70 pro‐inflammatory cytokines/chemokines was observed in patients with SE compared with patients without SE, in serum and CSF. Serum innate immunity pro‐inflammatory cytokines/chemokines (CXCL8, CCL2, and MIP‐1α) were significantly higher in patients with cNORSE compared to non‐cryptogenic RSE. Patients with NORSE with elevated innate immunity serum and CSF cytokine/chemokine levels had worse outcomes at discharge and at several months after the SE ended.Interpretation: We identified significant differences in innate immunity serum and CSF cytokine/chemokine profiles between patients with cNORSE and non‐cryptogenic RSE. The elevation of innate immunity pro‐inflammatory cytokines in patients with NORSE correlated with worse short‐ and long‐term outcomes. These findings highlight the involvement of innate immunity‐related inflammation, including peripherally, and possibly of neutrophil‐related immunity in cNORSE pathogenesis and suggest the importance of utilizing specific anti‐inflammatory interventions. ANN NEUROL 2023;94:75–90Keywords
Funding Information
- Philippe Foundation
- Institut Servier
This publication has 53 references indexed in Scilit:
- Long‐term follow‐up of febrile infection–related epilepsy syndromeEpilepsia, 2011
- Modulation of peripheral cytotoxic cells and ictogenesis in a model of seizuresEpilepsia, 2011
- Efficacy of Anti-Inflammatory Therapy in a Model of Acute Seizures and in a Population of Pediatric Drug Resistant EpilepticsPLOS ONE, 2011
- Chronic exposure to the chemokine CCL3 enhances neuronal network activity in rat hippocampal culturesJournal of Neuroimmunology, 2010
- Epileptogenesis Provoked by Prolonged Experimental Febrile Seizures: Mechanisms and BiomarkersJournal of Neuroscience, 2010
- Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticusJournal of Neuroinflammation, 2009
- Antagonism of peripheral inflammation reduces the severity of status epilepticusNeurobiology of Disease, 2009
- A role for leukocyte-endothelial adhesion mechanisms in epilepsyNature Medicine, 2008
- The Chemokine CXCL1/Growth Related Oncogene Increases Sodium Currents and Neuronal Excitability in Small Diameter Sensory NeuronsMolecular Pain, 2008
- New Roles for Interleukin-1 Beta in the Mechanisms of EpilepsyEpilepsy Currents, 2007